Vicente Corrêa Júnior1, Flávio Danni Fuchs2, Beatriz D Schaan3,4, Leila Beltrami Moreira5, Sandra Costa Fuchs5, Miguel Gus2. 1. Postgraduate Program in Medicine: Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Brazil. vicentecorreajunior@terra.com.br. 2. Division of Cardiology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 3. Postgraduate Program in Medicine: Endocrinology, School of Medicine, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Brazil. 4. Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 5. Postgraduate Program in Medicine: Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Brazil.
Abstract
OBJECTIVE: Part of the beneficial effects of metformin on the prevention of cardiovascular events in diabetes can be attributed to pleiotropic effects, including a blood pressure (BP)-lowering effect. In a double-blind parallel clinical trial (NCT02072382), the effect of metformin on BP evaluated by ambulatory blood pressure monitoring (ABPM) was measured. METHODS:Ninety-seven patients with hypertension, but without diabetes mellitus, were randomized to receive 850-1700 mg of metformin (n = 48) or placebo (n = 49). Clinical, laboratory, and ABPM data were collected at the baseline and after 8 weeks of follow-up. RESULTS: The sample consisted mainly of White overweight women. There was no difference in BP reduction measured by ABPM between both groups. There was no effect in BP measured in the different periods of ABP monitoring and office BP. Additionally, fasting plasma glucose, lipids, and C-reactive protein remained unchanged during the trial. There was a significant reduction in waist circumference with metformin (95.1 ± 10.4 to 89.3 ± 27.4 cm; p = 0.02). CONCLUSION: In the present trial, metformin did not reduce BP, measured by ABP monitoring, in hypertensive patients without diabetes.
RCT Entities:
OBJECTIVE: Part of the beneficial effects of metformin on the prevention of cardiovascular events in diabetes can be attributed to pleiotropic effects, including a blood pressure (BP)-lowering effect. In a double-blind parallel clinical trial (NCT02072382), the effect of metformin on BP evaluated by ambulatory blood pressure monitoring (ABPM) was measured. METHODS: Ninety-seven patients with hypertension, but without diabetes mellitus, were randomized to receive 850-1700 mg of metformin (n = 48) or placebo (n = 49). Clinical, laboratory, and ABPM data were collected at the baseline and after 8 weeks of follow-up. RESULTS: The sample consisted mainly of White overweight women. There was no difference in BP reduction measured by ABPM between both groups. There was no effect in BP measured in the different periods of ABP monitoring and office BP. Additionally, fasting plasma glucose, lipids, and C-reactive protein remained unchanged during the trial. There was a significant reduction in waist circumference with metformin (95.1 ± 10.4 to 89.3 ± 27.4 cm; p = 0.02). CONCLUSION: In the present trial, metformin did not reduce BP, measured by ABP monitoring, in hypertensivepatients without diabetes.
Authors: A Enrique Caballero; Adriano Delgado; Carlos A Aguilar-Salinas; Alberto Naranjo Herrera; Jose Luis Castillo; Tatiana Cabrera; Francisco J Gomez-Perez; Juan A Rull Journal: J Clin Endocrinol Metab Date: 2004-08 Impact factor: 5.958
Authors: Luiz Guilherme Kraemer de Aguiar; Luciana R Bahia; Nivaldo Villela; Camila Laflor; Fernando Sicuro; Nicolas Wiernsperger; Daniel Bottino; Eliete Bouskela Journal: Diabetes Care Date: 2006-05 Impact factor: 19.112
Authors: Caroline S Fox; Sean Coady; Paul D Sorlie; Ralph B D'Agostino; Michael J Pencina; Ramachandran S Vasan; James B Meigs; Daniel Levy; Peter J Savage Journal: Circulation Date: 2007-03-12 Impact factor: 29.690
Authors: Elizabeth Selvin; Shari Bolen; Hsin-Chieh Yeh; Crystal Wiley; Lisa M Wilson; Spyridon S Marinopoulos; Leonard Feldman; Jason Vassy; Renee Wilson; Eric B Bass; Frederick L Brancati Journal: Arch Intern Med Date: 2008-10-27
Authors: Nicole L Guthrie; Mark A Berman; Katherine L Edwards; Kevin J Appelbaum; Sourav Dey; Jason Carpenter; David M Eisenberg; David L Katz Journal: JMIR Cardio Date: 2019-03-12